Skip Navigation


NDT Advance Access originally published online on August 24, 2004
Nephrology Dialysis Transplantation 2004 19(11):2784-2788; doi:10.1093/ndt/gfh470
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/11/2784    most recent
gfh470v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gæde, P.
Right arrow Articles by Pedersen, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gæde, P.
Right arrow Articles by Pedersen, O.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant Vol. 19 No. 11 © ERA-EDTA 2004; all rights reserved


Original Article

Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria

Peter Gæde1, Lise Tarnow1, Pernille Vedel1, Hans-Henrik Parving1,2 and Oluf Pedersen1,2

1 Steno Diabetes Center and 2 Faculty of Health Science, University of Aarhus, Denmark

Correspondence and offprint requests to: Peter Gæde, Steno Diabetes Center, Gentofte, Denmark. Email: p.gaede{at}dadlnet.dk

Background. Intervention studies in microalbuminuric type 2 diabetic patients have demonstrated that it is possible to avoid progression to overt diabetic nephropathy and even to achieve regression to normoalbuminuria. However, the long-term impact of stabilization/regression in albuminuria on decline in glomerular filtration rate (GFR) has not been established.

Methods. 151 patients with type 2 diabetes and microalbuminuria at baseline in whom GFR was measured at least three times during 7.8 years of follow-up were divided into three groups according to the level of albuminuria during follow-up. Overt nephropathy was diagnosed as a urinary albumin excretion rate (AER) >300 mg/24 h and remission to normoalbuminuria was defined as an AER <30 mg/24 h at the last examination.

Results. During follow-up, 46 patients achieved remission to normoalbuminuria, 58 remained microalbuminuric and 47 patients progressed to overt nephropathy. The mean (± SE) yearly decline in GFR was lowest (2.3±0.4 ml/min/year) in patients who obtained remission, in comparison with patients remaining microalbuminuric, in whom the decline was 3.7±0.4 ml/min/year, and patients progressing to overt nephropathy, who had a decline in GFR of 5.4±0.5 ml/min/year (ANOVA, P<0.001). Start of antihypertensive treatment during follow-up was strongly associated with remission to normoalbuminuria [odds ratio: 2.32; 95% confidence interval (CI): 1.09–4.93] whereas a decrease in HbA1c by 1% increased the probability for remission (odds ratio: 1.48; 95% CI: 1.11–1.97).

Conclusions. Remission to normoalbuminuria was associated with a decreased GFR decline during 7.8 years of follow-up in type 2 diabetic patients with microalbuminuria. Antihypertensive therapy and improved glycaemic control were independent predictors for remission.

Keywords: glomerular filtration rate; kidney function; remission; risk reduction; type 2 diabetes mellitus; urinary albumin excretion rate


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Diabetes CareHome page
H. Kramer, D. Reboussin, A. G. Bertoni, S. Marcovina, E. Lipkin, F. L. Greenway III, F. L. Brancati, and the Look Ahead Research Group
Obesity and Albuminuria Among Adults With Type 2 Diabetes: The Look AHEAD (Action for Health in Diabetes) Study
Diabetes Care, May 1, 2009; 32(5): 851 - 853.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
B. E. de Galan, V. Perkovic, T. Ninomiya, A. Pillai, A. Patel, A. Cass, B. Neal, N. Poulter, S. Harrap, C.-E. Mogensen, et al.
Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes
J. Am. Soc. Nephrol., April 1, 2009; 20(4): 883 - 892.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
K. Khavandi, A. S. Greenstein, K. Sonoyama, S. Withers, A. Price, R. A. Malik, and A. M. Heagerty
Myogenic tone and small artery remodelling: insight into diabetic nephropathy
Nephrol. Dial. Transplant., February 1, 2009; 24(2): 361 - 369.
[Full Text] [PDF]


Home page
Ther Adv Cardiovasc DisHome page
S. Maeda
Review: Genetics of diabetic nephropathy
Therapeutic Advances in Cardiovascular Disease, October 1, 2008; 2(5): 363 - 371.
[Abstract] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. H. Brantsma, S. J.L. Bakker, D. de Zeeuw, P. E. de Jong, R. T. Gansevoort, and for the PREVEND Study Group
Extended Prognostic Value of Urinary Albumin Excretion for Cardiovascular Events
J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1785 - 1791.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
T. H. Jafar, N. Chaturvedi, J. Hatcher, and A. S. Levey
Use of albumin creatinine ratio and urine albumin concentration as a screening test for albuminuria in an Indo-Asian population
Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2194 - 2200.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
S.-i. Araki, M. Haneda, D. Koya, H. Hidaka, T. Sugimoto, M. Isono, K. Isshiki, M. Chin-Kanasaki, T. Uzu, and A. Kashiwagi
Reduction in Microalbuminuria as an Integrated Indicator for Renal and Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Diabetes, June 1, 2007; 56(6): 1727 - 1730.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. H. Brantsma, J. Atthobari, S. J.L. Bakker, D. de Zeeuw, P. E. de Jong, R. T. Gansevoort, and for the PREVEND Study Group
What Predicts Progression and Regression of Urinary Albumin Excretion in the Nondiabetic Population?
J. Am. Soc. Nephrol., February 1, 2007; 18(2): 637 - 645.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. L. Caramori, P. Fioretto, and M. Mauer
Enhancing the Predictive Value of Urinary Albumin for Diabetic Nephropathy
J. Am. Soc. Nephrol., February 1, 2006; 17(2): 339 - 352.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
T. Yamada, M. Komatsu, I. Komiya, Y. Miyahara, Y. Shima, M. Matsuzaki, Y. Ishikawa, R. Mita, M. Fujiwara, N. Furusato, et al.
Development, Progression, and Regression of Microalbuminuria in Japanese Patients With Type 2 Diabetes Under Tight Glycemic and Blood Pressure Control: The Kashiwa Study
Diabetes Care, November 1, 2005; 28(11): 2733 - 2738.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
S.-i. Araki, M. Haneda, T. Sugimoto, M. Isono, K. Isshiki, A. Kashiwagi, and D. Koya
Factors Associated With Frequent Remission of Microalbuminuria in Patients With Type 2 Diabetes
Diabetes, October 1, 2005; 54(10): 2983 - 2987.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.